Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

2019 ◽  
Author(s):  
Chiara Cremolini ◽  
Carlotta Antoniotti ◽  
Daniele Rossini ◽  
Sara Lonardi ◽  
Fotios Loupakis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomised Controlled Trial ◽  
Metastatic Colorectal Cancer ◽  
Controlled Trial ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Randomised Controlled

scholarly journals Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

2014 ◽  
Vol 15 (1) ◽  
pp. 78-86 ◽  
Author(s):  
Hugo E R Ford ◽  
Andrea Marshall ◽  
John A Bridgewater ◽  
Tobias Janowitz ◽  
Fareeda Y Coxon ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Symptom Control ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Randomised Controlled

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

The Lancet ◽  
2012 ◽  
Vol 380 (9839) ◽  
pp. 358-365 ◽  
Author(s):  
Axel Hauschild ◽  
Jean-Jacques Grob ◽  
Lev V Demidov ◽  
Thomas Jouary ◽  
Ralf Gutzmer ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Metastatic Melanoma ◽  
Controlled Trial ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document